title: Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
abstract: The low-molecular-weight imidazoquinolinamine derivative, 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (imiquimod, previously described as R-837), induced alpha-interferon (IFN-alpha) in mice. IFN induction was identified at oral doses as low as 3 mg/kg. The 10% lethal dose for daily treatment with imiquimod was 200 mg/kg. Oral treatment with 30 mg/kg imiquimod once every three days significantly inhibited MC-26 colon carcinoma. Delay of treatment from day 1 to day 5, when tumors were easily palpable, did not reduce benefits. Ten daily treatments were slightly more effective than five. However, delivery of the same total dose of imiquimod either once every day for 20 days, once every 4 days, once every 7 days, or once every 10 days inhibited tumor growth to the same level. The antitumor effects of imiquimod were significantly abrogated by an antiserum to murine IFN-alpha, suggesting that the antitumor effect was to a substantial extent mediated by IFN induction. Imiquimod also significantly reduced the number of lung colonies in mice inoculated i.v. with MC-26 tumor cells. Combination of treatment with imiquimod and cyclophosphamide was significantly (P less than 0.01) better than treatment with either drug alone. Combination treatment with cyclophosphamide led to cures in some of the mice inoculated either s.c. or i.v. with MC-26 cells. Treatment with imiquimod also inhibited the growth of RIF-1 sarcoma and Lewis lung carcinoma but was ineffective for P388 leukemia. Imiquimod is an oral IFN-alpha inducer with antitumor effectiveness for transplantable murine tumors.
authors.affiliation: Cancer Center, Medical College of Wisconsin, Milwaukee 53226.
authors.forename: Y A
authors.initials: YA
authors.lastname: Sidky
authors.forename: E C
authors.initials: EC
authors.lastname: Borden
authors.forename: C E
authors.initials: CE
authors.lastname: Weeks
authors.forename: M J
authors.initials: MJ
authors.lastname: Reiter
authors.forename: J F
authors.initials: JF
authors.lastname: Hatcher
authors.forename: G T
authors.initials: GT
authors.lastname: Bryan
mesh_terms: D000634:Aminoquinolines / Q000627:therapeutic use*; D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D000077271:Imiquimod; D007106:Immune Sera / Q000276:immunology; D007369:Interferon Inducers / Q000627:therapeutic use*; D007372:Interferons / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011817:Rabbits; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000634:Aminoquinolines; D007106:Immune Sera; D007369:Interferon Inducers; D014409:Tumor Necrosis Factor-alpha; D003520:Cyclophosphamide; D007372:Interferons; D000077271:Imiquimod